C M Bidwell & Associates Ltd. Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

C M Bidwell & Associates Ltd. acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 3,801 shares of the biopharmaceutical company's stock, valued at approximately $351,000.

A number of other large investors also recently modified their holdings of GILD. Public Sector Pension Investment Board lifted its holdings in Gilead Sciences by 13.4% in the third quarter. Public Sector Pension Investment Board now owns 54,122 shares of the biopharmaceutical company's stock worth $4,538,000 after purchasing an additional 6,400 shares during the period. PDT Partners LLC purchased a new position in Gilead Sciences in the third quarter valued at about $1,770,000. Edgestream Partners L.P. lifted its stake in Gilead Sciences by 94.5% in the third quarter. Edgestream Partners L.P. now owns 23,917 shares of the biopharmaceutical company's stock valued at $2,005,000 after acquiring an additional 11,618 shares during the last quarter. ARGA Investment Management LP grew its stake in Gilead Sciences by 0.3% in the 3rd quarter. ARGA Investment Management LP now owns 864,786 shares of the biopharmaceutical company's stock valued at $72,504,000 after buying an additional 2,959 shares during the last quarter. Finally, Bellevue Group AG lifted its holdings in shares of Gilead Sciences by 18.2% during the third quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company's stock worth $3,859,000 after buying an additional 7,093 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently commented on GILD. JPMorgan Chase & Co. increased their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. The Goldman Sachs Group boosted their price objective on Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research report on Wednesday, February 12th. Piper Sandler boosted their price target on Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a research note on Wednesday, February 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a "hold" rating to a "buy" rating and increased their target price for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $105.12.

Remove Ads

Gilead Sciences Trading Down 1.9 %

Shares of Gilead Sciences stock traded down $2.14 on Friday, hitting $110.25. The stock had a trading volume of 5,371,465 shares, compared to its average volume of 8,576,443. The stock has a 50 day moving average of $107.02 and a 200 day moving average of $95.63. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $119.96. The firm has a market capitalization of $137.28 billion, a P/E ratio of 298.02, a PEG ratio of 0.71 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Friday, March 14th were given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.87%. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.77. The ex-dividend date of this dividend was Friday, March 14th. Gilead Sciences's payout ratio is presently 854.05%.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 17,929 shares of the company's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $118.17, for a total value of $2,118,669.93. Following the sale, the chief financial officer now owns 169,061 shares in the company, valued at $19,977,938.37. This represents a 9.59 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In the last three months, insiders have sold 302,785 shares of company stock valued at $30,503,250. 0.16% of the stock is owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.